| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Prodcut name | Oxaliplatin | |
| MOQ | 1G | |
| CAS | 61825-94-3 | |
| Appearance | White powder | |
| Molecular Formula | C8H14N2O4Pt | |
| Molecular Weight | 397.06 | |
| Assay | 99% |
Eloxatin was launched in France for second-line treatment of metastatic colorectal cancer. Oxaliplatin is a second generation platinum drug prepared in three steps from either k2tCl4 or K2Ptl4. It has an antitumor spectrum similar to cisplatin, however, it is more effective against L1210 leukemia and cisplatin resistant L1210. It is also effective against B16 melanoma but has a dose limiting toxicity of peripheral sensory neuropathy that is reversible upon cessation of the drug. The (R,R)- enantiomer has greater activity than the (S,S)-isomer but this is tumor line dependent, e.g., there was no difference found for P-388 or Sarcoma 180. Clinical drug administration based on circadium timing showed it was better tolerated when given 16 h after the onset of light. Oxaliplatin binds to guanineN7 and can lead to bidentate chelation that results in the bending of DNA. This feature is recognized by high mobility group proteins (HMG) which impedes repair reactions and stops replication and transcription.
Antitumor drug, used in the treatment of rectal cancer.
A- For colorectal cancer, ovarian cancer has good curative effect.
B- For gastric cancer, non-hodgkin's lymphoma, non-small cell lung cancer, head and neck cancer have certain curative effect
C- Colorectal cancer patientsI nvalid treated by 5 - FU, resistance to other platinum, Oxaliplatin is still effective.
){kind=link}